Strongbridge Biopharma plc Announces Promotion of Fredric Cohen, M.D., to Chief Medical Officer
November 29 2016 - 8:00AM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
biopharmaceutical company focused on the development and
commercialization of novel therapies for rare diseases, today
announced the promotion of Fredric Cohen, M.D., to chief medical
officer. In this role, Dr. Cohen will continue to lead
Strongbridge’s clinical development and regulatory activities for
COR-003 (levoketoconazole), the Company’s lead product candidate
for endogenous Cushing’s syndrome, and COR-005 (veldoreotide), in
development for acromegaly. Dr. Cohen will also be responsible for
the Company’s medical affairs. Dr. Cohen will continue to report
directly to Matthew Pauls, president and chief executive officer.
“Fred’s depth and breadth of industry and
clinical development experience has proven to be a significant
asset to the organization. Tremendous unmet needs remain in the
diagnosis and treatment of rare diseases, and we are confident in
Fred’s ability to lead and execute on the clinical development of
both COR-003 and COR-005. As we continue executing against our
strategic plan to build a global rare disease Company, we look
forward to Fred’s ongoing contributions along with his leadership
of our clinical and medical affairs teams,” said Matthew Pauls,
president and chief executive officer of Strongbridge
Biopharma.
Dr. Cohen joined Strongbridge in 2015 and has
held roles of increasing responsibility, including senior vice
president, global research and development, and vice president,
clinical research and development. Dr. Cohen is an endocrinologist
by training with more than 20 years of drug and business
development experience, most recently focused in development and
commercialization of rare disease and specialty products. Prior to
joining Strongbridge, Dr. Cohen provided strategic and operational
counsel to life science companies, actively supporting their
development and licensing functions. Prior to that, he served as
executive director, clinical pipeline, at Aptalis Pharma, where he
was responsible for innovation strategy as well as building and
advancing the company’s specialty pharma pipeline. He has also held
research and development positions with Johnson & Johnson and
Eli Lilly & Company. Dr. Cohen earned his M.D. from
Pennsylvania State University College of Medicine and an AB in
biology from Franklin and Marshall College.
About Strongbridge
Biopharma Strongbridge Biopharma is a global
biopharmaceutical company focused on the development and
commercialization of novel therapies for rare diseases.
Strongbridge’s lead product candidate, COR-003 (levoketoconazole),
is a cortisol inhibitor currently being studied in the global Phase
3 SONICS trial for the treatment of endogenous Cushing's syndrome.
Strongbridge’s rare endocrine disease franchise also includes
COR-005, a next-generation somatostatin analog (SSA) being
investigated for the treatment of acromegaly, with potential
additional applications in Cushing's syndrome and neuroendocrine
tumors. Both COR-003 and COR-005 have received orphan designation
from the U.S. Food and Drug Administration and
the European Medicines Agency. For more information,
visit www.strongbridgebio.com.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press release,
are forward-looking statements. These statements relate to future
events and involve known and unknown risks, including, without
limitation, uncertainties regarding Strongbridge's strategy, plans
and objectives of management for future operations. The words
"anticipate," "estimate," "expect," "intend," "may," "plan,"
"potential," "project," "target," "will," "would," or the negative
of these terms or other similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections and are not guarantees of
future performance or development and involve known and unknown
risks, uncertainties and other factors. The forward-looking
statements contained in this press release are made as of the date
of this press release, and Strongbridge Biopharma does
not assume any obligation to update any forward-looking statements
except as required by applicable law.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2023 to Apr 2024